The objective of this study was to determine if the current dosage regimen for chloramphenicol (CAP) administered to children with severe malaria (SM) for presumptive treatment of concomitant bacterial meningitis achieves steady state plasma CAP concentrations within the reported therapeutic range of 10-25 mg/l. Fifteen children (11 male, 4 female) with a median age of 45 months (range: 10-108 months) and having SM, were administered multiple intravenous doses (25 mg/kg, 6 hourly for 72 h) of chloramphenicol sodium succinate (CAPS) for presumptive treatment of concomitant bacterial meningitis. Blood samples were collected over 72 h, and plasma CAPS, CAP and CSF CAP concentrations determined by high performance liquid chromatography. Average steady state CAP concentrations were approximately 17 mg/l, while mean fraction unbound (0.49) and CSF/plasma concentration ratio (0.65) were comparable to previously reported values in Caucasian children. Clearance was variable (mean^4.3 l/h), and trough plasma concentrations during the first dosing interval were approximately 6 mg/l. Simulations indicated that an initial of loading dose of 40 mg/kg CAPS, followed by a maintenance dose of 25 mg/kg every 6 h would result in trough CAP concentrations of approximately 10 mg/l and peak concentrations _25 mg/l throughout the treatment period. The current dosage regimen for CAP needs to include a loading dose of 40 mg/kg CAPS to rapidly achieve plasma CAP concentrations within the reported therapeutic range.
Introduction
Severe falciparum malaria is a major cause of childhood mortality in sub-Saharan Africa, 1, 2 Bacterial infections often complicate severe malaria in children. In Kenyan children admitted to hospital with malaria, 7.8 per cent have been shown to have a bacteraemia and this is associated with a three fold increase in mortality. 3, 4 Furthermore, it is difficult to clinically distinguish between cerebral malaria and bacterial meningitis, and antimicrobials are often administered until the results of the lumbar puncture are known. 5 Thus, in resource poor countries (RPCs), presumptive treatment with chloramphenicol and benzyl penicillin is often started until the cultures of blood and cerebrospinal fluid (CSF) are available.
In severely ill children, chloramphenicol is administered intravenously as the inactive prodrug, chloramphenicol sodium succinate, which has no antibacterial activity, and must be hydrolysed in the liver to generate the active chloramphenicol. The bioavailability of chloramphenicol from the intravenously administered prodrug is determined both by the extent of hydrolysis and renal excretion of the prodrug. 6 Studies in children 6, 7 and adults 8 have shown that hydrolysis of chloramphenicol succinate to chloramphenicol in vivo is often incomplete and variable. In infants and children, the clearance of chloramphenicol and chloramphenicol succinate has been reported to exhibit wide interindividual variability. Furthermore, there is evidence suggesting that hepatocellular dysfunction associated with infections could impair metabolism of chloramphenicol. 9 The therapeutic range for chloramphenicol is thought to be between 10-20 mg/l, 10, 11 and dose-related toxicity is associated with peak concentrations 425 mg/l. 12 Chloramphinicol is included in the WHO list of essential drugs, and is still widely used in many RPCs because it is cheap and readily available. Its pharmacokinetics have been described in African infants 53 months 13 but detailed pharmacokinetics in older African children have only been reported in two studies in malnourished children. 14, 15 Thus, the current dosage regimens for chloramphenicol in many RPCs have not been evaluated in many of the populations in which they are used. In particular, malaria infection in children may be associated with a degree of hepatic dysfunction 2 that may affect the pharmacokinetics of chloramphenicol. Children with malaria also receive other concurrent drugs such as phenytoin, phenobarbitone and paracetamol which have been reported to interact with chloramphenicol. [16] [17] [18] [19] We have studied the pharmacokinetics of intravenous chloramphenicol succinate in children with SM to assess whether the current dosage regimen rapidly achieves plasma chloramphenicol concentrations within the range of 10-25 mg/l.
Methods

Setting
The study was conducted at the Kenya Medical Research Institute (KEMRI) Unit, Kilifi District Hospital (KDH), on the Kenyan coast. The study formed part of a larger study on the effect of concomitant administration of chloramphenicol on pharmacokinetics of phenytoin in children with severe malaria and bacterial infections, 20 and was approved by the KEMRI Ethics Committee.
Patients
Children admitted to the KEMRI paediatric ward at the KDH were recruited into the study if: (i) they were aged 9 months to 13 years; (ii) they had features of severe falciparum malaria 1 and; (iii) if the parents/ guardian gave a written informed consent. Details of the clinical management have been described elsewhere. 20 Chloramphenicol administration and blood and CSF sampling Chloramphenicol sodium succinate (Lincoln Pharmaceuticals Ltd., Nirav Complex, Ahmedabad, India) was administered intravenously (25 mg/kg, 6 hourly for 72 h) as a bolus over 1 min. Blood samples (0.4 ml), from which plasma was obtained for measuring chloramphenicol and chloramphenicol succinate concentrations, 21 were collected at various times over 72 h. In those patients who had a lumbar puncture performed for clinical purposes, an aliquot (100 ml) of CSF was obtained and stored at À20 C until assayed for chloramphenicol. 21 Pharmacokinetic analysis Plasma chloramphenicol and chloramphenicol succinate concentration-time data during the first 6 h dosing interval were simultaneously fitted to the model shown in Fig. 1 , using the pharmacokinetic programme TopFit. 22 Simulations of plasma chloramphenicol concentrations were also performed using TopFit. Estimated pharmacokinetic parameters were 
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Results Fifteen children (4 females and 11 males) were recruited into the study (Table 1) .
Estimated mean steady state total chloramphenicol concentrations (C ss ) were within the reported therapeutic range of 10-25 mg/l (Table 2) , although trough concentrations were 510 mg/l after the first dose. Simulations indicated that a loading dose of 40 mg/kg, followed by a maintenance dose of 25 mg/ kg every 6 h would rapidly achieve and maintain plasma chloramphenicol concentrations within the therapeutic range throughout the treatment period (Fig. 2) . Lumbar punctures were performed within a median time of 5 h (range: 2-6 h) after administration of the last dose of chloramphenicol succinate. Concentrations of chloramphenicol in CSF ranged from 4.4 to 13.2 mg/l (Fig. 3) , above the MIC for all the isolates Streptococcus pneumoniae, the main cause of bacterial meningitis in this hospital. 24 
Discussion
Chloramphenicol is still routinely used in resourcepoor countries (RPCs) for treatment of bacterial infections including bacterial meningitis despite concerns about its adverse effects, since it is cheap, widely available and a broad-spectrum antibiotic. The regimen we studied is recommended by the WHO and the British National Formulary, and is widely used in health facilities in rural Africa. It does not include administration of a loading dose. Based on the pharamcokinetic data generated from this study, we recommend that an initial loading dose of 40 mg/kg be administered to ensure that chloramphenicol trough and peak concentrations of approximately 10 and 20 mg/l, respectively, are achieved during the first 6 h when such children are most critically ill. Most children in this study received paracetamol for treatment of fever. In addition, all children received phenytoin. Although these drugs have been reported to interact with chloramphenicol, 16, 18, 19 we did not find any significant effect of concomitant administration of these drugs on the clearance of chloramphenicol.
The mean CSF: plasma chloramphenicol concentration ratio estimated in this study (0.62) was similar to previously reported values in Caucasian children and infants. 25 In addition, concentrations of chloramphenicol in CSF from different children at different times after drug administration were all !4 mg/l (Fig. 3) . The MIC for Streptococcus pneumonia, the main causative agent for bacterial meningitis in children admitted to this hospital, 24 was estimated to be 2 mg/l, while the National Committee for Clinical Laboratory Standards criteria for sensitive isolates is an MIC 4 mg/l. Taken together, these results support the use of chloramphenicol for presumptive treatment of pneumoccocal meningitis in our setting.
Conclusions and Recommendations
We have shown that the pharmacokinetics of chloramphenicol in African children with severe malaria are broadly similar to previous reports in Caucasian children. Concomitantly administered paracetamol and phenytoin do not appear to have any effect on chloramphenicol pharmacokinetics. To achieve and maintain therapeutic chloramphenicol concentrations rapidly and throughout the treatment period, we recommend that a loading dose of 40 mg/kg chloramphenicol sodium succinate, followed by a maintenance dose of 25 mg/kg every 6 h should be administered. 
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